David Sterman

Analyst Articles

The first rule of running a biotech company: Don’t run low on cash. Once investors smell a cash squeeze coming, they’ll hammer shares mercilessly. That was the painful lesson learned by the executives at Dynavax Technologies (NASDAQ: DVAX). Though DVAX was pursuing the development of a very promising new vaccine,… Read More

As summer wrapped up, consumers’ moods grew sour. Fears of a looming government shutdown led many to simply stop spending on discretionary items, leading to a cycle of lower profit forecasts for a number of retailers. Few appear to have been as hard hit as women’s apparel and accessory retailer Francesca’s… Read More

Warren Buffett loves to invest in stable businesses with few competitors. One of his recent favorites is DaVita HealthCare (NYSE: DVA), which operates a network of dialysis treatment centers in the United States catering to patients that have diabetes-induced kidney failure. Buffett’s Berkshire Hathaway (NYSE: BRK-B) has been a steady buyer… Read More

For the past 20 years, you’ve been working on computers that store information on hard disk drives. These turntable-like devices, made by companies such as Western Digital (NASDAQ: WDC) and Seagate Technology (NASDAQ: STX), have benefited from tremendous improvements, enabling these drives to hold ever-larger amounts of data. But the… Read More

By many measures, 2013 is shaping up to be the best year for initial public offerings (IPOs) since 2007. The volume of new offerings has surged, and hot new issues such as FireEye (NASDAQ: FEYE), Rally Software Development (NYSE: RALY) and Epizyme (NASDAQ: EPZM) have already bagged triple-digit gains. A… Read More